文献速递关节外科骨质疏松与代谢性骨病

唑来膦酸对绝经后骨质疏松女性初次全髋关节置换术后假体周围骨密度及骨代谢标志物的影响

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
PubMed 文献 · Osteoporos Int · 2019-05-21

研究纳入40例绝经后骨质疏松女性,随机分为对照组(钙+骨化三醇)和唑来膦酸组(钙+骨化三醇+唑来膦酸),比较全髋关节置换术后假体周围骨密度和骨代谢标志物。唑来膦酸组在术后6个月和12个月多个假体周围分区骨密度丢失显著少于对照组,β-CTX显著降低。结论认为术后静脉输注5 mg唑来膦酸可有效减少假体周围骨密度丢失并改善骨重建。

要点

  • 唑来膦酸组在术后6个月和12个月多个假体周围分区骨密度丢失显著少于对照组。
  • 唑来膦酸组术后3、6、12个月β-CTX水平显著低于对照组。
  • TP1NP仅在术后12个月两组间有统计学差异。

核心结论

  • 全髋关节置换术后静脉输注5 mg唑来膦酸可有效减少绝经后骨质疏松女性假体周围骨密度丢失并改善骨重建。

研究设计与样本

  • 2015年11月至2016年4月纳入40例符合标准的女性患者,随机分为对照组(钙+骨化三醇)和唑来膦酸组(钙+骨化三醇+唑来膦酸)。

主要发现

  • 术后6个月,对照组在1、4、6、7区的骨密度丢失较唑来膦酸组更显著。
  • 术后12个月,对照组在1、2、4、6、7区的骨密度丢失较唑来膦酸组更显著。
  • 术后3、6、12个月,唑来膦酸组骨吸收标志物β-CTX水平显著低于对照组。
  • 骨形成标志物TP1NP仅在术后12个月两组间有统计学差异。

临床怎么用

  • 作者认为唑来膦酸治疗对全髋关节置换术后骨质疏松患者可能具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To investigate the effect of zoledronic acid on periprosthetic bone mineral density (BMD) and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. METHODS: From November 2015 to April 2016, 40 female patients who met the inclusion criteria were randomized into two groups: a control group (calcium + calcitriol) and a zoledronic acid group (calcium + calcitriol + zoledronic acid). At 1 week and 3, 6, and 12 months after operation, BMD was obtained through dual-energy X-ray absorptiometry (DEXA). At pre-operation and at 3, 6, and 12 months after the operation, levels of bone metabolism markers were obtained by serum examination. RESULTS: Loss of BMD was significantly more pronounced in the control group than in the ZOL group in zones 1, 4, 6, and 7 at 6 months and in zones 1, 2, 4, 6, and 7 at 12 months after the operation. The levels of bone-resorption marker (β-CTX) were significantly lower in the ZOL group than in the control group at 3, 6, and 12 months after operation. The levels of bone-formation marker (TP1NP) performed statistically differences only at 12 months after the operation in these two groups. CONCLUSIONS: Receiving an intravenous infusion of 5 mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis. Zoledronic acid significantly inhibited bone mass loss in zones 1, 2, 4, 6, and 7 after THA and inhibited bone-resorption marker (β-CTX) to improve bone remodeling. Zoledronic acid treatment is potentially important for patients with osteoporosis after THA.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Zhou W, Liu Y, Guo X, et al. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int. 2019. PMID: 31115592. doi:10.1007/s00198-019-05005-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。